Radiprodil is an investigational drug with demonstrated potential for treating seizures associated with GRIN-related neurodevelopmental disorders, a condition caused by gain-of-function mutations in the GRIN2B gene. Clinical trials have shown that radiprodil is well-tolerated and significantly reduces seizure frequency in affected individuals. It is a selective, potent negative allosteric modulator of the NR2B subunit of the NMDA receptor, which helps to control overactive brain activity characteristic of these disorders. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include RGH-896, (1-Piperidineacetamide, N-(2 and 3-dihydro-2-oxo-6-benzoxazolyl)-4-[(4-fluorophenyl)methyl]-alpha-oxo-). Its PubChem CID is 10200813.
Radiprodil
| CAS No | 496054-87-6 |
|---|---|
| Molecular Formula | C21H20FN3O4 |
| Molecular Weight | 397.4 g/mol |
| Synonyms | 2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]-2-oxo-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Radiprodil is an investigational drug with demonstrated potential for treating seizures associated with GRIN-related neurodevelopmental disorders, a condition caused by gain-of-function mutations in the GRIN2B gene.
The listed CAS number is 496054-87-6.
The listed molecular formula is C21H20FN3O4.
The listed molecular weight is 397.4 g/mol.
2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]-2-oxo-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide.
The source lists RGH-896, (1-Piperidineacetamide, N-(2 and 3-dihydro-2-oxo-6-benzoxazolyl)-4-[(4-fluorophenyl)methyl]-alpha-oxo-).